Hannah Chang, M.D.
- Medical Oncology
- Breast Cancer
- Assistant Professor, Department of Medical Oncology & Therapeutics Research
Hannah Chang, M.D., is an assistant professor of medical oncology and therapeutics research at City of Hope® Cancer Center Duarte, where she specializes in working with breast cancer patients and conducting leading-edge clinical trials focused on developing novel therapies for high-risk patients.
Dr. Chang attended Chicago Medical School at Rosalind Franklin University of Medicine and Science. She completed an internal medicine internship and residency and a hematology-oncology fellowship at UT Southwestern Medical School in Dallas, Texas. She also held the position of research associate in the Department of Cell Biology at City of Hope Duarte.
Dr. Chang's is motivated by the lifelong relationships that oncologists develop with patients and their families. She integrates her clinical and research expertise to identify unmet needs among high-risk breast cancer patients and addresses them through innovative clinical trials and translational research. Her work has been published in multiple peer-reviewed journals. Outside of medicine, Dr. Chang enjoys spending time with her husband and two sons.
Education & Experience
- 2024, Board Certified, American Board of Internal Medicine (ABIM), Medical Oncology
- 2024, Board Certified, American Board of Internal Medicine (ABIM), Hematology
- 2021, Board Certified, American Board of Internal Medicine (ABIM)
- 2018, Doctor of Medicine, Chicago Medical School at Rosalind Franklin University, North Chicago, Illinois
- 2021, Residency, Internal Medicine, University of Texas Southwestern, Dallas, Texas
- 2024, Fellowship, Hematology and Oncology, University of Texas Southwestern, Dallas, Texas
- 2018, Internship, Internal Medicine, University of Texas Southwestern, Dallas, Texas
- 2024-present, Assistant Professor, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California
Awards & Memberships
AWARDS
- Alpha Omega Alpha (AOA) Alpha Omega Alpha Honor Society
- Centennial Scholarship Chicago Medical School
- Jerome R. Share Memorial Scholarship Chicago Medical School
- Best Oral Presentation Society of Academic Emergency Medicine
- Weinberg Undergraduate Research Grant Northwestern University
- Dean’s List Northwestern University
MEMBERSHIPS
- Metastatic Breast Cancer Research Conference Advocate Research Program (MARP)
- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
Publications
- Chang, H.L., Schwettmann, B., McArthur, H.L. and Chan, I.S., 2023. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. Journal of Clinical Investigation, 133(18), p.e172156.
- Chang, H, and Jones, A L, 2021. Current status of biologics in perioperative treatment for resectable or borderline resectable liver metastases. Current colorectal cancer reports, 17, pp.10-22.
- Hong, A S, Chang, H, Courtney, DM, Fullington, H, Lee, SJC, Sweetenham, JW and Halm, EA, 2021. Patterns and results of triage advice before emergency department visits made by patients with cancer. JCO oncology practice, 17(4), pp.e564-e574.
- Lu, H and Dowell, J, 2020. Osimertinib in pulmonary manifestations: two case reports and review of the literature. in vivo, 34(1), pp.315-319.
- Hsu, PY, Wu, VS, Kanaya, N, Petrossian, K, Hsu, HK, Nguyen, D, Schmolze, D, Kai, M, Liu, CY, Lu, H and Chu, P, 2018. Dual mTOR Kinase Inhibitor MLN0128 sensitizes HR+/HER2+ breast cancer patient-derived xenografts to trastuzumab or fulvestrantMLN0128 with trastuzumab or fulvestrant in HR+/HER2+ PDXs. Clinical cancer research, 24(2), pp.395-406.
- Kanaya, N, Nguyen, DM, Lu, H, Wang, YZ, Hsin, LY, Petreas, M, Nelson, D, Guo, W, Reynolds, P, Synold, T and Chen, S, 2015. AroER tri-screen™ is a novel functional assay to estimate both estrogenic and estrogen precursor activity of chemicals or biological specimens. Breast cancer research and treatment, 151, pp.335-345.
- Chen, S, Hsieh, JH, Huang, R, Sakamuru, S, Hsin, LY, Xia, M, Shockley, KR, Auerbach, S, Kanaya, N, Lu, H and Svoboda, D, 2015. Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10K library. Toxicological sciences, 147(2), pp.446-457.
- Mehta, HM, Futami, M, Glaubach, T, Lee, DW, Andolina, JR, Yang, Q, Whichard, Z, Quinn, M, Lu, HF, Kao, WM and Przychodzen, B, 2014. Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition. Leukemia, 28(5), pp.1041-1051.
- Mehta, HM, Glaubach, T, Long, A, Lu, H, Przychodzen, B, Makishima, H, McDevitt, MA, Cross, NCP, Maciejewski, J and Corey, SJ, 2013. Granulocyte colony-stimulating factor receptor T595I (T618I) mutation confers ligand independence and enhanced signaling. Leukemia, 27(12), pp.2407-2410.
- Lu, H, Blatt, J, and Corey, SJ, 2013. Trends, outcomes, and characteristics of pediatric oncology phase I and II studies: A systematic review. Pharmaceutical medicine, 27, pp.235-244.